•  
  •  
 

Abstract

The polymorphism in the vitamin D receptor gene FokI position is used to evaluate the polymorphism impact on the levels of vitamin D, testosterone and prolactin hormones in the sera of patients with prostate cancer and benign prostatic hyperplasia vs. healthy controls. The vitamin D receptor gene Fok1 restriction site was amplified and examined by TaqMan RT-PCR technique. It was found that the TT genotype played a protective effect in 70% and 50% in prostate cancer and benign prostatic hyperplasia patients respectively. While, the CC genotype was found to be 100% disease-attributed genotype in both prostate cancer and benign prostate hyperplasia. Also, the distribution of genotypes (TT, TC and CC) was not consistent with Hardy Weinberg equation in the patients with prostate cancer as a significant difference was found by chi-square test (X2 > 3.84) at P ≥ 0.05 between the observed and expected frequencies. But wasn't seen in patients with BPH or control group. The level of vitamin D was significantly affected by the genotype CC of VDR-FOK I in prostate cancer patients compared with TT and TC genotypes. There were no significant differences in Vit. D level among the three genotypes in the patients with BPH and the healthy control group. In association with genotypes, the levels of testosterone and prolactin did not differ significantly among the studied groups. It could be concluded that the vitamin D receptor FokI polymorphism is associated with Iraqi prostate cancer patients more than in benign prostate hyperplasia with vitamin D deficiency in blood serum.

Keywords

Benign prostate hyperplasia, Prostate cancer, Prolactin, Testosterone, VDR-Fok1 polymorphism

Subject Area

Biology

Article Type

Article

First Page

878

Last Page

885

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Download

Share

COinS